Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

The flurry of deals comes as Roche is facing biosimilar competition for its ‘big three’ antibodies – Rituxan ... biotech says is linked to a growing list of diseases including pancreatic ...

The drug will only be given to patients who do not respond or who progress during or up to 6 months after treatment with rituximab (Roche ... Mabthera facing biosimilar competition The deal ...

2020-2035 List of Figures Figure 01: Global Water for Injection Market Value Share Analysis, By Type, 2024 and 2035 Figure 02: Global Water for Injection Market Attractiveness Analysis, By Type, ...

Rituxan (rituximab) is not safe to receive while pregnant or breastfeeding. Certain factors, including the risk of fetal harm, may determine whether you should receive Rituxan treatment during ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available ... STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current ...